In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
The antimicrobial activities of garenoxacin and eight other antibiotics against 641 anaerobic isolates were evaluated with the NCCLS agar dilution method. Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0.25 and 2; Fusobacterium spp., 0.25 and 0.5; Porphyromonas spp., 0.125 and 0.25; Bilophila wadsworthia, 0.5 and 1; Veillonella spp., 0.25 and 0.5; Clostridium spp., 0.25 and 1; Clostridium difficile, 2 and >64; Bifidobacterium spp., 1 and 2; Eggerthella lenta, 0.25 and 1; Propionibacterium spp., 0.5 and 0.5; gram-positive cocci, 0.125 and 0.25.
Liebetrau
A
A
Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Leipzig, Germany. liea@medizin.uni-leipzig.de
Rodloff
A C
AC
Behra-Miellet
J
J
Dubreuil
L
L
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000201:enzymology; D001424:Bacterial Infections / Q000382:microbiology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000032:analysis / Q000378:metabolism
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D001618:beta-Lactamases; C419689:garenoxacin